摘要
【摘 要】 目的：分析头孢哌酮 /舒巴坦不同输注持续时间治疗重症肺炎的疗效。方法：选取我院 2018年 1月至 2019年 1月收治的重症肺炎患者 60例，将其随机分为 2组，各 30例。采用头孢哌酮 /舒巴坦对两组进行静脉滴注，当患者中性粒细胞、血液白细胞百分比、临床症状、体温等恢复正常后，观察组持续输注 3d，而对照组仅持续输注 1d。比较两组临床症状如体温升高、气促、肺部啰音、咳嗽等复发情况。结果：经治疗，观察组出现 1例体温升高、 1例气促，疾病复发率 6.67%，而对照组出现 3例体温升高、 1例气促、 3例肺部啰音、 1例咳嗽，疾病复发率为 26.67%，观察组较对照组显著较低，且 P<0.05差异有统计学意义。结论：重症肺炎患者采用头孢哌酮 /舒巴坦治疗期间，当各项指标复常后在持续输注 3d，则可有效减少各症状复发率，因此值得临床应用推广。
【关键词】 重症肺炎 ;头孢哌酮 /舒巴坦 ;不同输注持续时间 ;疗效分析
[Abstract] Objective: to analyze the therapeutic effect of Cefoperazone / sulbactam in the treatment of severe pneumonia. Methods: 60 patients with severe pneumonia admitted to our hospital from January 2018 to January 2019 were randomly divided into two groups, 30 in each group. Cefoperazone / sulbactam were infused intravenously in the two groups. When the neutrophils, the percentage of white blood cells, clinical symptoms and body temperature returned to normal, the observation group continued to infuse for three days, while the control group only continued to infuse for one day. The clinical symptoms such as temperature rise, shortness of breath, lung rale and cough were compared between the two groups. Results: after treatment, there was 1 case of temperature rise and 1 case of shortness of breath in the observation group, with a recurrence rate of 6.67%, while in the control group, there were 3 cases of temperature rise, 1 case of shortness of breath, 3 cases of lung rales and 1 case of cough, with a recurrence rate of 26.67%, which was significantly lower in the observation group than in the control group, with a statistically significant difference (P < 0.05). Conclusion: during the treatment of severe pneumonia patients with Cefoperazone / sulbactam, continuous infusion for 3 days after the normalization of each index can effectively reduce the recurrence rate of each symptom, so it is worthy of clinical application and promotion.
出版日期
2020年06月12日（中国期刊网平台首次上网日期，不代表论文的发表时间）
